AKESO (09926.HK): FDA Issues CRL on Ivonescimab US BLA
NewTimeSpace News: On 16 November 2026, Akeso, Inc. (stock code: 09926) announced that it has noted the press release published by Summit Therapeutics Inc. (NASDAQ: SMMT) on 15 November 2026 regarding the Complete Response Letter (CRL) received from the US Food and Drug Administration for ivonescimab's Biologics License Application based on the HARMONi study.
The announcement was made at the request of The Stock Exchange of Hong Kong Limited under Rule 13.10 of the Listing Rules. Having made such enquiry as is reasonable in the circumstances, the Company confirmed that, save for the CRL which might have caused the unusual price movements of its shares, the Board is not aware of any reasons for the price movements, nor of any information that must be announced to avoid a false market in its securities or any inside information requiring disclosure under Part XIVA of the Securities and Futures Ordinance.
- AKESO (09926.HK): Trustee Buys 336,000 Shares for About HK$21m
- AKESO (09926.HK): Phase III Results for Ivonescimab in First-Line Biliary Tract Cancer at ESMO
- AKESO (09926.HK): Completes 20m-share placing, nets HK$1.94bn
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit